Nyxoah’s Genio Shows Promise for OSA Management

Nyxoah (NYXH) has released an update.

Nyxoah SA showcased positive outcomes at the International Surgical Sleep Society meeting from their DREAM study on the Genio implant for treating Obstructive Sleep Apnea (OSA), with significant reductions in Apnea-Hypopnea Index (AHI) and improvements in patients’ quality of life. Over 80% of participants achieved an AHI below 15 after 12 months, indicating effective management of OSA. The company is now moving towards FDA approval, marking a significant step in making Genio available in the US.

For further insights into NYXH stock, check out TipRanks’ Stock Analysis page.